Effect and Safety of Sorafenib in Advanced Hepaotocellular Carcinoma: a Systematic Review_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 YIPeng-sheng , ZHANGMing ,  XUMing-qing

Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;

Corresponding?author：

XUMing-qing, Email: xumingqing@163.com

Keywords：

Sorafenib; Advanced hepatocellular carcinoma; Effect; Safety; Meta analysis

DOI：

10.7507/1007-9424.20140303

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the effect and safety of sorafenib in patients with advanced hepatocellular carcinoma(HCC). Methods The computer-based search in Pubmed, Embase, Science Citation Index, and Cochrane for phaseⅡandⅢclinical trial related to sorafeinib in advanced HCC were conducted. Data abstraction and quality assessment were conducted according to enrolled criteria. Meta-analysis was performed by REVMAN 5.2 version, evidence recommendation was conducted by GRADE 3.6 version, which classify evidence level into:extremely low quality evidence, low quality evidence, moderate quality evidence, and high quality evidence. Results Five studies were included, 4 randomization control trial(RCT), 1 prospective no-randomization control clinical trial. Meta-analysis indicated that overall survival, time to progression, and disease control rate in sorafenib treatment group were higher than those in control group(P < 0.05). In addition, the incidence of hand-foot skin reaction, rash/desquamation, hypertention, and dirrahea in soafeinib treatment group were higher than those in control group(P < 0.05). Conclusion Sorafeinib can prolong the overall survival, time to progression, and disease control rate in patients with advanced HCC, but there is still no evidence that sorafenib can improve tumor response in these patients.

Citation： YIPeng-sheng, ZHANGMing, XUMing-qing. Effect and Safety of Sorafenib in Advanced Hepaotocellular Carcinoma: a Systematic Review. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(10): 1268-1276. doi: 10.7507/1007-9424.20140303 Copy

1.	Qu XD, Chen CS, Wang JH, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma[J]. BMC Cancer, 2012, 12:263.
2.	Murata S, Mine T, Ueda T, et al. Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma[J]. Scientific World J, 2013, 2013:479805.
3.	Varga M, Valsamis A, Matia I, et al. Transarterial chemoembolization in hepatocellular carcinoma[J]. Rozhl Chir, 2009, 88(8):434-438.
4.	Biolato M, Marrone G, Racco S, et al. Transarterial chemoembolization (TACE) for unresectable HCC:a new life begins?[J]. Eur Rev Med Pharmacol Sci, 2010, 14(4):356-362.
5.	Duan F, Wang MQ, Liu FY, et al. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis[J]. Asia Pac J Clin Oncol, 2012, 8(2):156-163.
6.	Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma[J]. Hepatology, 2008, 48(4):1312-1327.
7.	Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma[J]. Biologics, 2008, 2(4):779-788.
8.	Personeni N, Rimassa L, Pressiani T, et al. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2013, 139(7):1179-1187.
9.	Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012:current status and future perspectives[J]. Semin Oncol, 2012, 39(4):493-502.
10.	Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma[J]. Semin Oncol, 2012, 39(4):486-492.
11.	Zhang X, Yang XR, Huang XW, et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review[J]. Hepatobiliary Pancreat Dis Int, 2012, 11(5):458-466.
12.	Zhang T, Ding X, Wei D, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma:a meta-analysis of randomized trials[J]. Anticancer Drugs, 2010, 21(3):326-332.
13.	Connock M, Round J, Bayliss S, et al. Sorafenib for the treatment of advanced hepatocellular carcinoma[J]. Health Technol Assess, 2010, 14 Suppl 1:17-21.
14.	Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma:a systematic review of the literature[J]. Dig Dis Sci, 2013, 58(12):3389-3396.
15.	Shen A, Tang C, Wang Y, et al. A systematic review of sorafenib in child-pugh a patients with unresectable hepatocellular carcinoma[J]. J Clin Gastroenterol, 2013, 47(10):871-880.
16.	Trojniak MP, Palozzo AC, Mazurek M, et al. Sorafenib in hepatocellular carcinoma-a post marketing evaluation[J]. Immunopharmacol Immunotoxicol, 2012, 34(3):419-422.
17.	Nakano M, Tanaka M, Kuromatsu R, et al. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma[J]. Oncology, 2013, 84(2):108-114.
18.	胡安斌, 何曉順, 邰強, 等.索拉非尼在預防和治療肝癌肝移植術后腫瘤復發中的療效評價[J].中華醫學雜志, 2012, 92(18):1264-1267.
19.	Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sora-fenib in patients with advanced hepatocellular carcinoma:subanal-yses of a phaseⅢtrial[J]. J Hepatol, 2012, 57(4):821-829.
20.	Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status[J]. J Oncol Pract, 2014, 10(5):e335-e341.
21.	Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines:10.Considering resource use and rating the quality of economic evidence[J]. J Clin Epidemiol, 2013, 66(2):140-150.
22.	Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
23.	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
24.	Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial[J]. JAMA, 2010, 304(19):2154-2160.
25.	Kudo M, Imanaka K, Chida N, et al. PhaseⅢstudy of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14):2117-2127.
26.	Bai W, Wang YJ, Zhao Y, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma:a propensity score matching study[J]. J Dig Dis, 2013, 14(4):181-190.
27.	曾憲濤, 冷衛東, 李勝, 等.如何正確理解及使用GRADE系統[J].中國循證醫學雜志, 2011, 11(9):985-990.
28.	皋文君, 劉硯燕, 袁長蓉.國際腫瘤化療藥物不良反應評價系統——通用不良反應術語標準4.0版[J].腫瘤, 2012, 32(2):142-144.
29.	張嵐, 任正剛.索拉菲尼治療肝癌常見不良反應及處理的研究進展[J].中國腫瘤臨床, 2013, 40(20):1268-1271.

1. Qu XD, Chen CS, Wang JH, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma[J]. BMC Cancer, 2012, 12:263.
2. Murata S, Mine T, Ueda T, et al. Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma[J]. Scientific World J, 2013, 2013:479805.
3. Varga M, Valsamis A, Matia I, et al. Transarterial chemoembolization in hepatocellular carcinoma[J]. Rozhl Chir, 2009, 88(8):434-438.
4. Biolato M, Marrone G, Racco S, et al. Transarterial chemoembolization (TACE) for unresectable HCC:a new life begins?[J]. Eur Rev Med Pharmacol Sci, 2010, 14(4):356-362.
5. Duan F, Wang MQ, Liu FY, et al. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis[J]. Asia Pac J Clin Oncol, 2012, 8(2):156-163.
6. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma[J]. Hepatology, 2008, 48(4):1312-1327.
7. Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma[J]. Biologics, 2008, 2(4):779-788.
8. Personeni N, Rimassa L, Pressiani T, et al. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2013, 139(7):1179-1187.
9. Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012:current status and future perspectives[J]. Semin Oncol, 2012, 39(4):493-502.
10. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma[J]. Semin Oncol, 2012, 39(4):486-492.
11. Zhang X, Yang XR, Huang XW, et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review[J]. Hepatobiliary Pancreat Dis Int, 2012, 11(5):458-466.
12. Zhang T, Ding X, Wei D, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma:a meta-analysis of randomized trials[J]. Anticancer Drugs, 2010, 21(3):326-332.
13. Connock M, Round J, Bayliss S, et al. Sorafenib for the treatment of advanced hepatocellular carcinoma[J]. Health Technol Assess, 2010, 14 Suppl 1:17-21.
14. Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma:a systematic review of the literature[J]. Dig Dis Sci, 2013, 58(12):3389-3396.
15. Shen A, Tang C, Wang Y, et al. A systematic review of sorafenib in child-pugh a patients with unresectable hepatocellular carcinoma[J]. J Clin Gastroenterol, 2013, 47(10):871-880.
16. Trojniak MP, Palozzo AC, Mazurek M, et al. Sorafenib in hepatocellular carcinoma-a post marketing evaluation[J]. Immunopharmacol Immunotoxicol, 2012, 34(3):419-422.
17. Nakano M, Tanaka M, Kuromatsu R, et al. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma[J]. Oncology, 2013, 84(2):108-114.
18. 胡安斌, 何曉順, 邰強, 等.索拉非尼在預防和治療肝癌肝移植術后腫瘤復發中的療效評價[J].中華醫學雜志, 2012, 92(18):1264-1267.
19. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sora-fenib in patients with advanced hepatocellular carcinoma:subanal-yses of a phaseⅢtrial[J]. J Hepatol, 2012, 57(4):821-829.
20. Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status[J]. J Oncol Pract, 2014, 10(5):e335-e341.
21. Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines:10.Considering resource use and rating the quality of economic evidence[J]. J Clin Epidemiol, 2013, 66(2):140-150.
22. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
23. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
24. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial[J]. JAMA, 2010, 304(19):2154-2160.
25. Kudo M, Imanaka K, Chida N, et al. PhaseⅢstudy of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14):2117-2127.
26. Bai W, Wang YJ, Zhao Y, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma:a propensity score matching study[J]. J Dig Dis, 2013, 14(4):181-190.
27. 曾憲濤, 冷衛東, 李勝, 等.如何正確理解及使用GRADE系統[J].中國循證醫學雜志, 2011, 11(9):985-990.
28. 皋文君, 劉硯燕, 袁長蓉.國際腫瘤化療藥物不良反應評價系統——通用不良反應術語標準4.0版[J].腫瘤, 2012, 32(2):142-144.
29. 張嵐, 任正剛.索拉菲尼治療肝癌常見不良反應及處理的研究進展[J].中國腫瘤臨床, 2013, 40(20):1268-1271.

Previous Article
Analysis of Risk Factors for Acute Lower Deep Venous Thrombosis in Patients
Next Article
Mechanical Bowel Preparation for Elective Colorectal Surgery: Updated Systematic Review and Meta-Analysis

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Effect and Safety of Sorafenib in Advanced Hepaotocellular Carcinoma: a Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content